| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 71,45 | 71,50 | 14:21 | |
| 71,50 | 71,55 | 14:21 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 72,65 | 461 | |||
| 72,60 | 350 | |||
| 72,55 | 75 | |||
| 72,50 | 75 | |||
| 72,45 | 34 | |||
| 72,40 | 75 | |||
| 72,35 | 75 | |||
| 72,30 | 166 | |||
| 72,25 | 34 | |||
| 72,20 | 68 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/22ua.htm [/URL] | ||||
| 33 | 71,95 | |||
| 97 | 71,90 | |||
| 264 | 71,85 | |||
| 263 | 71,80 | |||
| 92 | 71,75 | |||
| 92 | 71,70 | |||
| 93 | 71,65 | |||
| 92 | 71,60 | |||
| 92 | 71,55 | |||
| 400 | 71,50 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.518 | 0,931 | 1.413 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 14:05:53 | 71,90 | 25 |
| 14:05:52 | 72,10 | 33 |
| 14:05:52 | 72,05 | 34 |
| 14:05:52 | 72,15 | 55 |
| 14:05:52 | 72,10 | 33 |
| 14:05:52 | 72,05 | 62 |
| 14:05:44 | 72,05 | 21 |
| 14:05:37 | 71,85 | 27 |
| 14:05:37 | 71,85 | 83 |
| 14:05:36 | 72,00 | 15 |
| 14:05:33 | 72,35 | 19 |
| 14:05:33 | 72,30 | 33 |
| 14:05:33 | 72,18 | 17 |
| 14:05:33 | 72,35 | 91 |
| 14:05:33 | 72,30 | 33 |
| 14:05:33 | 71,80 | 734 |
| 14:05:33 | 71,85 | 51 |
| 14:05:33 | 71,90 | 73 |
| 14:05:33 | 71,95 | 118 |
| 14:05:33 | 72,00 | 125 |
| Tagesumsatz Xetra | -15,05 -17,32 % | 584.408 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:03 | Biontech-Gründer kündigen Abschied an - Aktie bricht dramatisch ein | 49 | FOCUS | ||
| 13:54 | Sahin und Türeci verlassen Biontech - für die nächste mRNA-Revolution | 34 | Business Punk | ||
| 13:45 | BioNTech-Gründer Sahin und Türeci verlassen das Unternehmen - Aktie stürzt ab | 354 | 4investors | BioNTech-Mitgründer Ugur Sahin und Özlem Türeci werden das von ihnen aufgebaute Unternehmen bis Ende 2026 verlassen, um ein neues Biotechunternehmen mit Fokus auf mRNA-Technologien der nächsten Generation... ► Artikel lesen | |
| BIONTECH Aktie jetzt für 0€ handeln | |||||
| 13:42 | BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture | 14 | Benzinga.com | ||
| 13:39 | BioNTech-Gründerpaar verlässt Firma und gründet neues Unternehmen | 48 | Der Standard |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 12:48 | Trinity Biotech plc: Trinity Biotech Provides Business and Trading Update | GlobeNewswire (Europe) | DUBLIN, March 10, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable... ► Artikel lesen | |
| 13:14 | Aptevo Therapeutics: Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% | ACCESS Newswire | Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutics... ► Artikel lesen | |
| 13:38 | Dermata Therapeutics: Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing | ACCESS Newswire | - Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand - SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / Dermata Therapeutics, Inc. ("Dermata," or the "Company")... ► Artikel lesen | |
| 13:36 | Morning Market Movers: INKT, GSIW, ARQ, SciSparc See Big Swings | AFX News | BEIJING (dpa-AFX) - At 8:05 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 13:00 | Trinity Biotech plc: Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform | GlobeNewswire (Europe) | - Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization - Anticipating initiation of pivotal clinical trial in 2026 - Updated electronics... ► Artikel lesen |